CytRx Corp. buy melinda
Start price
19.05.17
/
50%
€2.73
Target price
25.05.17
€4.33
Performance (%)
23.59%
End price
25.05.17
€3.38
Summary
This prediction ended on 25.05.17 with a price of €3.38. The prediction had a final performance of 23.59%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| CytRx Corp. | - | - | - | - |
| iShares Core DAX® | 3.002% | 4.755% | 23.700% | 68.627% |
| iShares Nasdaq 100 | 2.966% | 0.363% | 8.027% | 116.238% |
| iShares Nikkei 225® | 5.606% | 4.528% | 20.313% | 56.217% |
| iShares S&P 500 | 2.312% | 1.811% | 5.451% | 70.924% |
Comments by melinda for this prediction
In the thread CytRx Corp. diskutieren
Gesundheit | Biotechnologie | Vereinigte Staaten
Die Registrierung für Phase 2 abgeschlossen ist . Diskussion des Poster auf der ASCO am 3. Juni 2017. Phase - 3 - Test für das dritte Quartal 2017 geplant.